Fig. 3.

Sorafenib could inhibit the upregulation of PD-L1 induced by doxorubicin in OS cells in vivo. PD-L1 expression was significantly increased in the doxorubicin group while decreased in the doxorubicin plus sorafenib group. A Flow cytometry analysis of PD-L1 expression on the surface of OS cells from subcutaneous tumors and B Quantification of the results. C. IHC analysis of PD-L1 expression in the tumor bed of subcutaneous tumors. Scale bar indicates 100 μm. All data are presented as the means ± SD. *p < 0.05